Lupin Of India Expects U.S. FDA Clearance For Problem Plant In March
This article was originally published in PharmAsia News
India's Lupin says it expects to have its dispute with U.S. FDA resolved by March, based on an upcoming agency inspection of a questionable plant
You may also be interested in...
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.